Home Page: JTO Clinical and Research Reports

Skip to Main Content

Articles in Press

Research Article
Open Access
The EGFR C797S mutation confers resistance to a novel EGFR inhibitor CLN-081 to EGFR exon 20 insertion mutations
Published online: January 24, 2023
Brief Report
Open Access
Application of the Novel Grading System of Invasive Pulmonary Adenocarcinoma in a Real Diagnostic Scenario: A Brief Report of 9353 Cases
Published online: January 24, 2023
Case Report
Open Access
Massive thymic hyperplasia masquerading as cancer: A case report and review of the literature
Published online: January 19, 2023
Case Report
Open Access
ALK-positive adenocarcinoma after acquired resistance to lorlatinib and transformation to small-cell lung cancer: a case report
Published online: January 19, 2023

Issue Highlights

Original ArticleOpen Access
Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Esophageal Cancer
Zhan et al.
Published online: October 20, 2022
Original ArticleOpen Access
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
Nicoś et al.
Published online: November 9, 2022
Case ReportOpen Access
Remarkable Intracranial Response to Sotorasib in a Patient With KRAS^G12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report
Yeh et al.
Published online: November 6, 2022
Case ReportOpen Access
Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
Riudavets et al.
Published online: November 9, 2022
Original ArticleOpen Access
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Lai et al.
Published online: September 21, 2022
Original ArticleOpen Access
Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial
Hibino et al.
Published online: October 14, 2022

About

Cover Image - JTO Clinical and Research Reports, Volume 3, Issue 12

JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing the following article types in particular: Phase I trials, Well performed single-arm phase II trials, More

Cover Image - Journal of Thoracic Oncology, Volume 18, Issue 2

Subscribe to Journal

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide.

Most Read (Last 30 Days)

Research Article
Open Access
Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with Atypical EGFR Activating Mutations: A Retrospective Multicenter Study
Published online: January 9, 2023
Original Article
Open Access
A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma
Published online: November 30, 2022
Research Article
Open Access
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor Based Systemic Therapy in BRAF-Mutation Positive Non-Small Cell Lung Cancer
Published online: January 9, 2023
Original Article
Open Access
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Published online: September 21, 2022
Original Article
Open Access
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study
Published online: October 28, 2022
Original Article
Open Access
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases
Published online: November 9, 2022

Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

RELX